One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Figure 1

(a) Time course of best-corrected visual acuity (BCVA); (b) difference in mean change in BCVA at month 3 and month 12 between the study groups. LD group: 3 loading doses followed by the pro re nata regimen (3 + PRN); PRN group: 1 dose followed by the PRN regimen (1 + PRN).